Avaliation the Therapeutic Effiacy of Fluconazol

  • Ítalo Jorge Alves Norões
  • Manuel Odorico Moraes
  • Tassia Tâmara Silva Feitosa
  • Lucas Severo Bonilha de Souza
  • Jucier Gonçalves Júnior
  • Modesto Leite Rolim-Neto
  • Maria do Socorro Vieira dos Santos
  • Cláudio Gleidiston Lima da Silva

Abstract

Leishmaniasis is a group of diseases with a large spectrum, cosmopolitan, but with broad and signifiant impact in the tropical zone. Leishmaniasis presents itself in two forms, one visceral involving hemolinfopoietic system structures, other with skin and/or mucosa involvement, often without visceralizing. The latter, known as American Cutaneous Leishmaniasis (ACL) is the aim of this study. One of the major problems in the ACL is treatment procedure using injectable formulations, with
risk for complications from the injection and the risk of damage to the liver and kidney function and cardiac complications. Several tests have demonstrated satisfactory results using Fluconazole®. In order to consolidate the results described in the literature, this study sought to demonstrate the therapeutic effiacy of Fluconazole® with high-dose treatment of ACL in patients from an endemic area in the Southern State of Ceará, Brazil, City of Barbalha. It’s conducted a prospective randomized study with two groups of patients. Sixty of the Group I: they were treated with 300mg or 450mg of Fluconazole® for six weeks. Sixty Group II: they were treated with Glucantime 20mg/kg/ day for 20 consecutive days. The diagnosis of ACL was performed with Imprint, culture, biopsy and histopathological stain with Giemsa and immunohistochemistry. Montenegro’s Intradermoreaction was also performed. All patients were evaluated clinically and followed up for ninety days. Continuous variables were evaluated by Student's t test, and for the correlation of variables the Pearson correlation coeffiient (r) was used. The time healing of each group had its evaluation by Kaplan-Meier method. In all tests the hypothesis α was considered signifiant when less than 5% (p <0.05). The therapeutic effiacy (TE) was calculated based on the reduction of relative risk. The study population was predominantly made up of individuals between 30 and 40 years, brown skin color, peasants, rural people, with a slight prevalence of females. The results showed therapeutic effiacy of 38.7%. The cure was related to the size of the lesion, relevant factor in the statistical p <0.0001. The lesions smaller than 30 mm (alone or sum of multiple lesions) responded promptly to Fluconazole®


Published
Jul 4, 2015
How to Cite
ALVES NORÕES, Ítalo Jorge et al. Avaliation the Therapeutic Effiacy of Fluconazol. International Archives of Medicine, [S.l.], v. 8, july 2015. ISSN 1755-7682. Available at: <http://imed.pub/ojs/index.php/iam/article/view/1231>. Date accessed: 14 dec. 2017. doi: http://dx.doi.org/10.3823/1734.
Section
Microbiology

Keywords

Cutaneous Leishmaniasis. Fluconazol. Meglumine.

Most read articles by the same author(s)

1 2 3 > >>